GnRH agonist pretreatment prior to frozen embryo transfer in women with adenomyosis: a systematic review and meta-analysis
Reproductive BioMedicine Online · 2025-11 · 51 (5) · 105075
DOI: 10.1016/j.rbmo.2025.105075 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Reproductive BioMedicine Online, 2025-11. Verfasst von Marcel Steinmann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecological Endocrinology and Reproductive Medicine, Women´s Hospital, Lucerne Cantonal Hospital, Lucerne, Switzerland. Electronic addr…. Hauptthemen laut MEDLINE: Embryo Transfer, Gonadotropin-Releasing Hormone, Adenomyosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
The aim of this study was to investigate whether gonadotrophin-releasing hormone agonist (GnRHa) pretreatment has a positive effect on pregnancy outcomes in women with adenomyosis who were undergoing a frozen embryo transfer (FET) cycle. A systematic search of the PubMed, Embase and Cochrane databases up to 20 March 2025 was conducted. The primary outcome was live birth rate, while secondary outcomes were the clinical pregnancy, implantation and miscarriage rates. Seven retrospective cohort studies and one randomized trial met the inclusion criteria. The meta-analysis of studies comparing GnRHa pretreatment plus hormone replacement therapy (HRT)-FET with HRT-FET alone in women with adenomyosis showed a comparable live birth rate (six studies, odds ratio [OR] 1.19, 95% CI 0.69-2.06, I2 = 74%), clinical pregnancy rate (seven studies, OR 1.36, 95% CI 0.83-2.23, I2 = 80%), miscarriage rate (six studies, OR 1.09, 95% CI 0.69-1.74, I2 = 20%) and implantation rate per embryo transfer (three studies, OR 1.38, 95% CI 0.59-3.24, I2 = 90%). Current evidence does not demonstrate the superiority of GnRHa pretreatment plus HRT over HRT alone in women with adenomyosis prior to FET. Future randomized trials are needed to determine the optimal protocol for FET in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecological Endocrinology and Reproductive Medicine, Women´s Hospital, Lucerne Cantonal Hospital, Lucerne, Switzerland. Electronic address: marcel.steinmann@luks.ch.
- OVA IVF, Clinic Zurich, Zurich, Switzerland.
- Division of Gynecological Endocrinology and Reproductive Medicine, Women´s Hospital, Lucerne Cantonal Hospital, Lucerne, Switzerland; Division of Gynecological Endocrinology and Reproductive Medicine, Women's University…
- Brussels IVF, Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Jette, Belgium.
- Department of Obstetrics and Gynecology, Cantonal Hospital of Schaffhausen, Schaffhausen, Switzerland.
- Division of Gynecological Endocrinology and Reproductive Medicine, Women's University Hospital, Inselspital Bern, University of Bern, Switzerland.
Zitieren
APA
Steinmann, M., Anthon, C., Kohl Schwartz, A. S., Mackens, S., Blockeel, C., Kalaitzopoulos, D. R., & Vidal, A. (2025). GnRH agonist pretreatment prior to frozen embryo transfer in women with adenomyosis: a systematic review and meta-analysis. Reproductive BioMedicine Online, 51(5), 105075. https://doi.org/10.1016/j.rbmo.2025.105075
Vancouver
Steinmann M, Anthon C, Kohl Schwartz AS, Mackens S, Blockeel C, Kalaitzopoulos DR, et al. GnRH agonist pretreatment prior to frozen embryo transfer in women with adenomyosis: a systematic review and meta-analysis. Reproductive BioMedicine Online. 2025;51(5):105075. doi:10.1016/j.rbmo.2025.105075
BibTeX
@article{Steinmann2025,
author = {Steinmann, Marcel and Anthon, Christiane and Kohl Schwartz, Alexandra S and Mackens, Shari and Blockeel, Christophe and Kalaitzopoulos, Dimitrios R and Vidal, Angela},
title = {GnRH agonist pretreatment prior to frozen embryo transfer in women with adenomyosis: a systematic review and meta-analysis},
journal = {Reproductive BioMedicine Online},
year = {2025},
volume = {51},
number = {5},
pages = {105075},
doi = {10.1016/j.rbmo.2025.105075}
}
EUVIMED